UMIN-CTR Clinical Trial
| Unique ID issued by UMIN | UMIN000031215 |
|---|---|
| Receipt number | R000035508 |
| Scientific Title | Treatment of macular edema secondary to branch retinal vein occlusion with sub-tenon triamcinolone acetonide injection |
| Date of disclosure of the study information | 2018/03/01 |
| Last modified on | 2018/09/25 17:17:39 |
* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments
Basic information
Public title
Treatment of macular edema secondary to branch retinal vein occlusion with sub-tenon triamcinolone acetonide injection
Acronym
Treatment of macular edema following BRVO with STTA
Scientific Title
Treatment of macular edema secondary to branch retinal vein occlusion with sub-tenon triamcinolone acetonide injection
Scientific Title:Acronym
Treatment of macular edema following BRVO with STTA
Region
| Japan |
Condition
Condition
Macular edema following BRVO
Classification by specialty
| Ophthalmology |
Classification by malignancy
Others
Genomic information
NO
Objectives
Narrative objectives1
We evaluate efficacy and safety by observation group and sub-tenon triamcinolone acetonide injection (STTA) (product name:MaQaid ophthalmic injection 40mg) group for macular edema secondary to branch retinal vein occlusion, the patients have characteristics of good prognosis to natural course.
Basic objectives2
Safety,Efficacy
Basic objectives -Others
Trial characteristics_1
Confirmatory
Trial characteristics_2
Others
Developmental phase
Not applicable
Assessment
Primary outcomes
Central Retinal thickness (CRT) for both groups at four weeks.
Key secondary outcomes
Transition of CRT, area under the curve of CRT-monitoring period, logMAR visual acuity, metamorphopsia score, visual analog scale score about vision defect consciousness, and Kaplan-Meier curve based on the number of cases which meet withdrawal criteria and adverse event about VA or CRT.
Base
Study type
Interventional
Study design
Basic design
Parallel
Randomization
Randomized
Randomization unit
Individual
Blinding
Open -no one is blinded
Control
No treatment
Stratification
Dynamic allocation
Institution consideration
Blocking
Concealment
Intervention
No. of arms
2
Purpose of intervention
Treatment
Type of intervention
| Medicine |
Interventions/Control_1
STTA will be given on the STTA group and follow-up will be observed
Interventions/Control_2
Follow- up group will be observed
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10
Eligibility
Age-lower limit
| 20 | years-old | <= |
Age-upper limit
| 80 | years-old | > |
Gender
Male and Female
Key inclusion criteria
Select those who satisfies all the following criteria.
1) Age is between 20 years old and 79 years old.
2) Those whose eye has been diagnosed as BRVO-ME within 6 months before visiting screening inspection.
3) Those who have not been treated by topical medical therapy for BRVO-ME
4) Case that visual acuity and lesion of target patient satisfy the following both items.
a) Fractional eyesight is 0.5 or more.
b) Lesion of retinal vein branch obstruction lie within 2 papilla area or the shape of lesion wraps from the ear side.
5) Those whose intraocular pressure of the target eye is 21 mmHg or less.
6) Those who can agree the consent of participation for this research by free will in writing
Key exclusion criteria
1) The subject eye has retinal disease except BRVO.
2) Transparency of the subject eye is turbid.
3) Those who have active ocular infection or inactive toxoplasmosis.
4) Those who have glaucoma or ocular hypertension, or medical histories of them.
5) Those who have histories of herpetic infection in their subject eyes.
6) Those who have uncontrollable systemic disease.
7) Those who are systemic debility, or have severe heart disease, severe cerebral blood flow disorder or cirrhosis.
8) Serum creatinine is 2.0 mg/dL or more.
9) Those who have undergone vitreous surgery to the subject eye or who are expected to undergo vitreous surgery.
10) Those who have undertaken the following treatment within 24 weeks or who are expected to be undergone.
Administration of corticosteroid to thesubject eye below the Tenon capsule or retro-bulbar.
Intravitreal of drug to the subject eye.
Administration of immunosuppressant drug, immunomodulatory drug, antimetabolites drug and/or alkylating agents.
Hyperbaric oxygen therapy or stellate ganglion block.
Hemodialysis or peritoneal dialysis.
11) Those who have received laser or intraocular surgery in the subject eye within 12 weeks or who are expected to undergo them.
12) Those who have received treatments which are corticosteroid, oral carbonic anhydrase inhibitor, warfarin, heparin, heparin analogue, selective thrombin inhibitor, direct thrombin inhibitors or(/and) FXa inhibitors within 4 weeks. Those who are expected to undergo these therapies.
13) Those who are planning of ophthalmic surgery during the observation period.
14) Those who have drug allergy to the drugs which are used in this study.
15) Those who cannot sufficient dilate pupil for inspection.
16) Pregnant or lactating women.
Target sample size
60
Research contact person
Name of lead principal investigator
| 1st name | |
| Middle name | |
| Last name | Motohiro Kamei |
Organization
Aichi Medical University
Division name
Department of Ophthalmology
Zip code
Address
1-1 KarimataYazako, Nagakute, Aichi, 480-1195 JAPAN
TEL
0561-62-3311
motokamei@aichi-med-u.ac.jp
Public contact
Name of contact person
| 1st name | |
| Middle name | |
| Last name | Hasegawa Miyuki |
Organization
Aichi Medical University
Division name
Department of Ophthalmology
Zip code
Address
1-1 KarimataYazako, Nagakute, Aichi, 480-1195 JAPAN
TEL
0561-62-3311
Homepage URL
hasegawa.miyuki.883@mail.cichi-med-u.ac.jp
Sponsor or person
Institute
Aichi Medicak University
Department of Ophthalmology
Institute
Department
Personal name
Funding Source
Organization
Wakamoto Pharmaceutical. Co.ltd.
Organization
Division
Category of Funding Organization
Profit organization
Nationality of Funding Organization
Other related organizations
Co-sponsor
MIYAKE Eye Hospital
Kamiiida daiichi General hospital
Name of secondary funder(s)
IRB Contact (For public release)
Organization
Address
Tel
Secondary IDs
Secondary IDs
NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW
Institutions
Institutions
Other administrative information
Date of disclosure of the study information
| 2018 | Year | 03 | Month | 01 | Day |
Related information
URL releasing protocol
Publication of results
Unpublished
Result
URL related to results and publications
Number of participants that the trial has enrolled
Results
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description
Progress
Recruitment status
Terminated
Date of protocol fixation
| 2018 | Year | 01 | Month | 31 | Day |
Date of IRB
Anticipated trial start date
| 2018 | Year | 02 | Month | 28 | Day |
Last follow-up date
Date of closure to data entry
Date trial data considered complete
Date analysis concluded
Other
Other related information
Management information
Registered date
| 2018 | Year | 02 | Month | 08 | Day |
Last modified on
| 2018 | Year | 09 | Month | 25 | Day |
Link to view the page
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000035508
